Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month
October 01 2019 - 06:30AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage
biotechnology company specializing in targeted immunotherapy for
advanced breast cancer. October is Breast Cancer Awareness
Month, an annual campaign to increase awareness of the disease.
Significant progress has been made in breast cancer support,
prevention, detection, diagnosis, treatment and care – yet the
estimated 42,000 deaths per year in the U.S. still indicates a
grave need for more effective breast cancer treatments.
Breast Cancer: Facts &
Statistics (U.S.)
Per the American Cancer Society 2019 report:
- After skin cancer, breast cancer is the most frequently
diagnosed cancer in women, with 268,600 women and 2,670 men
expected to be diagnosed with invasive breast cancer in 2019;
- The average risk of a woman developing breast cancer sometime
in her life is about 12%. This means there is a 1 in 8 chance she
will develop breast cancer;
- Approximately 20% of breast cancers occur in women younger than
50 and 43% occur in women older than 65;
- Breast cancer deaths in 2019 are estimated at 42,260 (41,760
women, 500 men), making breast cancer the 2nd leading cause of
cancer death in women (after lung cancer).
Note from Chairman of the
Board
October 1st kicks off Breast Cancer Awareness
Month; yet sadly, for millions of Americans touched by the pain and
death of breast cancer, their Awareness is eternal.
BriaCell’s clinical aim to attack and destroy breast cancer tumors
is also eternal, as we tirelessly advance our targeted
immunotherapy clinical program, working with world-class cancer
centers to recruit and treat patients:
- St. Joseph Heritage Healthcare in Santa Rosa, California
- University of Miami/Sylvester in Plantation, Florida
- Cancer Center of Kansas (CCK) in Wichita, Kansas
- Thomas Jefferson University in Philadelphia, Pennsylvania
- Providence Regional Medical Center in Everett, Washington
Breast Cancer Awareness Month brings the awareness that BriaCell
is not treating ‘subjects’ or ‘n=’. We are treating women –
mothers, daughters, sisters, wives, friends. Breast cancer
kills 115 women in the U.S. each day. BriaCell’s
work has already demonstrated clinical benefit to some women (i.e.
tumor shrinkage without serious side effects) who had failed
multiple prior treatments.
BriaCell has truly emerged in 2019, with a
flurry of major corporate and clinical developments, each one
transformational on its own, including findings of synergistic
anti-tumor activity in our Combination Study of Bria-IMTTM with
pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.]
and a Clinical Trial Collaboration signed with Incyte
Corporation.
Most recently, on September 19 2019, BriaCell’s
President & CEO Dr. Bill Williams presented clinical updates of
our Phase I/IIa clinical trial of BriaCell’s Bria-IMT™ in a
Combination Study with pembrolizumab [KEYTRUDA®] at the Next Gen
Immuno-Oncology Congress in Philadelphia. Dr. Williams highlighted
BriaCell’s top responder: an extraordinary woman who experienced a
highly remarkable reduction in breast cancer tumors, including
breast cancer metastases in her adrenal gland and the outer lining
of her brain. She had failed 12 prior regimens with 16 agents
(13 chemotherapy agents and 3 hormonal agents). She remains on our
treatment regimen. The Combination Study is listed in
ClinicalTrials.gov as NCT03328026.
Going forward, BriaCell intends to present more
fulsome patient data sets at major cancer conferences, such as the
San Antonio Breast Cancer Symposium on December 10-14, 2019.
Finally, I encourage shareholders, prospective
shareholders and other stakeholders to contact me directly if you
wish to further understand the strategies we’ve deployed to achieve
our primary goals: accelerate BriaCell’s remarkable clinical work
while maximizing shareholder value.
Sincere Regards,
Jamieson BondarenkoDirector and
Chairman of the BoardBriaCell Therapeutics
Corp.jbondarenko@BriaCell.com
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a
Combination Study with immune checkpoint inhibitors such as
pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.
(NYSE: MRK)]. The Combination Study is listed in ClinicalTrials.gov
as NCT03328026.
BriaCell also has a non-exclusive clinical trial
collaboration with Incyte Corporation to evaluate the effects of
combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations of
compounds from Incyte’s development portfolio with Bria-IMT™ in
advanced breast cancer patients.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Feb 2024 to Mar 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2023 to Mar 2024